Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Long-term Extension Study of burosumab in X-linked hypophosphatemia
jRCT2080225188Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of burosumab in X-linked hypophosphataemia (XLH), rickets and osteomalacia, sponsored by Kyowa Kirin. Started May 2020; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)ricketsosteomalacia
Beyond the preview
Go deeper on jRCT2080225188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225188.